Advertisement

Canadian Journal of Public Health

, Volume 91, Supplement 1, pp S24–S28 | Cite as

Options de traitement pour les patients atteints d’hépatite C chronique

  • Kelly W. Burak
  • Samuel S. Lee
Article

Résumé

L’hépatite C est un grave problème de santé publique et il n’existe pas de thérapie vraiment efficace pour la combattre. Jusqu’à présent, la combinaison d’interféron et de ribavirin semble fournir la meilleure possibilité d’éradiquer le virus. Mais cette thérapie est coûteuse, assortie de nombreux effets secondaires et ne donne de bons résultats que chez la moitié des patients. Il faut développer de nouvelles stratégies pour alléger le fardeau croissant des maladies causées par l’hépatite C. Nous attendons avec impatience l’arrivée de nouveaux médicaments, notamment les inhibiteurs d’hélicase et de protéase.

Références

  1. 1.
    Marcellin P. Hepatitis C: The clinical spectrum of the disease. J Hepatol 1999;31(Suppl 1):9–16.CrossRefGoogle Scholar
  2. 2.
    Sherman M. Management of viral hepatitis: Clinical and public health perspectives - a consensus statement. CASL Hepatitis Consensus Group. Association canadienne pour l’étude du foie. Can J Gastroenterol 1997;11:407–16.CrossRefGoogle Scholar
  3. 3.
    National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997;23(3 Suppl 1):2S–10S.Google Scholar
  4. 4.
    Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996;24(4):778–89.CrossRefGoogle Scholar
  5. 5.
    Carithers RL, Emerson SS. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials. Hepatology 1997;26(3 Suppl 1):83S–88S.CrossRefGoogle Scholar
  6. 6.
    Mabee CL, Crippin JS, Lee WM. Review article: Interferon and hepatitis C - factors predicting therapeutic outcome. Aliment Pharmacol Ther 1998;12(6):509–18.CrossRefGoogle Scholar
  7. 7.
    Martinot-Peignoux M, Boyer N, Pouteau M, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998;29:214–23.CrossRefGoogle Scholar
  8. 8.
    Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997;113(2):558–66.CrossRefGoogle Scholar
  9. 9.
    Spengler U, Rockstroh JK. Hepatitis C in the patient with human immunodeficiency virus infection. J Hepatol 1998;29(6):1023–30.CrossRefGoogle Scholar
  10. 10.
    Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Intern Med 1997;127:875–81.CrossRefGoogle Scholar
  11. 11.
    Sim H, Yim C, Krajden M, Heathcote J. Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2 B. Am J Gastroenterol 1998; 93(1) :39–CrossRefGoogle Scholar
  12. 12.
    Bennett WG, Inouc Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-a 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855–65.CrossRefGoogle Scholar
  13. 13.
    Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-a therapy for chronic hepatitis C. Ann Intern Med 1997;127:866–74.CrossRefGoogle Scholar
  14. 14.
    Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999;29(1):264–70.CrossRefGoogle Scholar
  15. 15.
    Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141–47.CrossRefGoogle Scholar
  16. 16.
    Ajello A, Freni MA, Spadaro A, et al. Ten year follow-up of patients with chronic hepatitis C treated with interferon. Hepatogastroenterology 1999;46(28):2447–50.PubMedGoogle Scholar
  17. 17.
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhot-ic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131(3):174–81.CrossRefGoogle Scholar
  18. 18.
    Castro A, Suarez D, Inglada L, et al. Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C. J Interferon Cytokine Res 1997;17(1):27–30.CrossRefGoogle Scholar
  19. 19.
    Barbaro G, Di Lorenzo G, Soldini M, et al. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Scand J Gastroenterol 1999;34(9):928–33.CrossRefGoogle Scholar
  20. 20.
    Heathcote J. Consensus interferon: A novel interferon for the treatment of hepatitis C. J Vir Hepat 1998;5(Suppl 1):13–18.CrossRefGoogle Scholar
  21. 21.
    Anderson FH, Zeng L, Yoshida EM, Rock NR. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C. Can J Gastroenterol 1997;11(4):294–97.CrossRefGoogle Scholar
  22. 22.
    Zarski JP, Maynard-Mute M, Chousterman S, et al. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology 1998;27(3):862–67.CrossRefGoogle Scholar
  23. 23.
    Fabris P, Tositti G, Negro F, et al. Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients. Aliment Pharmocol Ther 1999;13(10):1329–34.CrossRefGoogle Scholar
  24. 24.
    Tsutsumi M, Takada A, Takase S, Sawada M. Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: A pilot study. J Gastroenter Hepatol 1996;11(11):1006–11.CrossRefGoogle Scholar
  25. 25.
    Komatsu M, Ishii T, Ono T, et al. Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration. Can J Gastroenterol 1997;11(6):507–11.CrossRefGoogle Scholar
  26. 26.
    Tanaka K, Kondo M, Sakaguchi T, et al. Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: Results of a long-term follow-up trial. J Gastroenterol Hepatol 1996;11(12):1155–60.CrossRefGoogle Scholar
  27. 27.
    Crosignani A, Budillon G, Cimino L, et al. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: A multicenter placebo-controlled study. Hepatogastroenterology 1998;45(23):1624–29.PubMedGoogle Scholar
  28. 28.
    van Rossum TG, Vulto AG, de Man RA, et al. Review article: Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 1998;12(3):199–205.CrossRefGoogle Scholar
  29. 29.
    Patrick L. Hepatitis C: Epidemiology and review of complementary/alternative medicine treatments. Altern Med Rev 1999;4(4):220–38.PubMedGoogle Scholar
  30. 30.
    Sherman KE, Sjogren M, Creager RL, et al. Combination therapy with thymosin alpha 1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial. Hepatology 1998;27(4):1128–35.CrossRefGoogle Scholar
  31. 31.
    Moscarella S, Buzzelli G, Romanelli RG, et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: Preliminary results. Liver 1998;18(5):366–69.CrossRefGoogle Scholar
  32. 32.
    Smith JP. Treatment of chronic hepatitis C with amantidine. Dig Dis Sci 1997;42(8):1681–87.CrossRefGoogle Scholar
  33. 33.
    Tabone M, Ercole E, Zaffino C, et al. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Italian J Gastroenterol Hepatol 1998;30(6):611–13.Google Scholar
  34. 34.
    Fong TL, Fried MW, Clarke-Platt J. A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy. Am J Gastroenterol 1999;94(4):990–93.CrossRefGoogle Scholar
  35. 35.
    Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol 1996;25(5):591–98.CrossRefGoogle Scholar
  36. 36.
    Schvarcz R, Yun AB, Sönnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995;46:43–47.CrossRefGoogle Scholar
  37. 37.
    Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961–66.CrossRefGoogle Scholar
  38. 38.
    Reichard O, Norkrons G, Fryden A, et al. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83–87.CrossRefGoogle Scholar
  39. 39.
    McHutchison J, Gordon S, Schiff E, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485–92.CrossRefGoogle Scholar
  40. 40.
    Poynard T, Marcellin P, Lee S, et al. Randomized trial of interferon 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426–32.CrossRefGoogle Scholar
  41. 41.
    Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999;39(2):550–55.CrossRefGoogle Scholar
  42. 42.
    Younossi Z, Singer M, McHutchison J, Shermock K. Cost effectiveness of interferon 2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318–24.CrossRefGoogle Scholar
  43. 43.
    Davis G, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493–99.CrossRefGoogle Scholar
  44. 44.
    Heathcote J, Keeffe E, Lee S, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136–43.CrossRefGoogle Scholar
  45. 45.
    Poynard T, McHutchison J, Goodman Z, et al. Is an “A la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000;31:211–18.CrossRefGoogle Scholar
  46. 46.
    Xu Z, Hoffman J, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetic/pharma-codynamics following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon a2a (IFN-a2a) to healthy subjects. Hepatology 1998;28(Suppl):702A.Google Scholar
  47. 47.
    Shiffman ML, Pockros PJ, Reddy RK, et al. A controlled, randomized, multicenter descending dose phase II trial of pegylated interferon a2a vs standard interferon a2a in patients with chronic hepatitis C. Gastroenterology 1999;116(suppl):A1275.Google Scholar
  48. 48.
    Nakamura H, Ito H, Ogawa H, et al. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load. Hepatogastroenterology 1999;46(26):1131–39.PubMedGoogle Scholar
  49. 49.
    Brillanti S, Foli M, Di Tomaso M, et al. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Italian J Gastroenterol Hepatol 1999;31(2):130–34.Google Scholar
  50. 50.
    Schalm SW, Brouwer JT, Bekkering FC, van Rossum TGJ. New treatment strategies in non-responder patients with chronic hepatitis C. J Hepatol 1999;31(Suppl 1):184–88.CrossRefGoogle Scholar
  51. 51.
    Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117(5):1164–72.CrossRefGoogle Scholar
  52. 52.
    Gish R. Future directions in the treatment of patients with chronic hepatitis C virus infection. Can J Gastroenterol 1999;13(1):57–62.CrossRefGoogle Scholar

Copyright information

© The Canadian Public Health Association 2000

Authors and Affiliations

  1. 1.Faculty of MedicineLiver Unit, University of CalgaryCanada

Personalised recommendations